Clinical trial · Interventional
To Evaluate Efficacy of Ursodeoxycholic Acid (UDCA) for the Prevention of Gallstone Formation After Gasterectomy
A Multi-center, Phase IV, Extension Study in PEGASUS-D Trial to Evaluate Efficacy of Ursodeoxycholic Acid (UDCA) for the Prevention of Gallstone Formation After Gastrectomy in Patients With Gastric Cancer
NCT05410535CI-TRIAL-00078392completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Of those patients who participated in PEGASUS-D FAS clinical trial, patient must sign the informed consent form in order to participate in this extension study. The medical records of the patients will be reviewed throughout the study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patients who continued UDCA 300mg medication | Drug | — | UNRESOLVED |
| Patients who discontinued UDCA 300mg prescription | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Patients who received UDCA 600mg
- description
- Patients who participated in PEGASUS-D clinical trial and received UDCA 600mg
- interventionNames
- Drug: Patients who continued UDCA 300mg medication
- Other: Patients who discontinued UDCA 300mg prescription
- type
- EXPERIMENTAL
- label
- Patients who received UDCA 300mg
- description
- Patients who participated in PEGASUS-D clinical trial and received UDCA 300mg
- interventionNames
- Drug: Patients who continued UDCA 300mg medication
- Other: Patients who discontinued UDCA 300mg prescription
- type
- PLACEBO_COMPARATOR
- label
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: Among the PEGASUS-D Full Analysis Set (FAS) subjects, those who agree to participate in this clinical trial or those who can collect retrospective cohort data after waiving consent according to the consent waiver criteria Exclusion Criteria: A person who, at the discretion of the investigator, is deemed difficult to participate in this clinical trial.
References
Publications (0)
Data not yet available
No reference posted for this study.